Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort

Detalhes bibliográficos
Autor(a) principal: Gomides, Ana Paula Monteiro
Data de Publicação: 2019
Outros Autores: Xavier, Ricardo Machado, Pinheiro, Geraldo da Rocha Castelar
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/216608
Resumo: The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
id UFRGS-2_fca3df8b065a142ef2fbb5dbf2534068
oai_identifier_str oai:www.lume.ufrgs.br:10183/216608
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Gomides, Ana Paula MonteiroXavier, Ricardo MachadoPinheiro, Geraldo da Rocha Castelar2020-12-17T04:09:46Z20191932-6203http://hdl.handle.net/10183/216608001119499The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.application/pdfengPloS one. San Francisco. Vol. 14, no. 3 (2019), e0213219, 7 p.Artrite reumatóideAntirreumáticosAdesão à medicaçãoMedicamentos sintéticosCauses of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohortEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001119499.pdf.txt001119499.pdf.txtExtracted Texttext/plain27727http://www.lume.ufrgs.br/bitstream/10183/216608/3/001119499.pdf.txtce63baec6093bf82da376483b3521a8bMD53001119499-02.pdf.txt001119499-02.pdf.txtExtracted Texttext/plain2045http://www.lume.ufrgs.br/bitstream/10183/216608/4/001119499-02.pdf.txt2d010f75fdbbc1104a5adeb568e150bdMD54ORIGINAL001119499.pdfTexto completo (inglês)application/pdf343894http://www.lume.ufrgs.br/bitstream/10183/216608/1/001119499.pdf91a9512521ad2d2a3116084368d593bbMD51001119499-02.pdfErrataapplication/pdf187818http://www.lume.ufrgs.br/bitstream/10183/216608/2/001119499-02.pdf9d8ad916eb6c4bca597effeb900c0783MD5210183/2166082020-12-18 05:13:22.506529oai:www.lume.ufrgs.br:10183/216608Repositório InstitucionalPUBhttps://lume.ufrgs.br/oai/requestlume@ufrgs.bropendoar:2020-12-18T07:13:22Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
title Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
spellingShingle Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
Gomides, Ana Paula Monteiro
Artrite reumatóide
Antirreumáticos
Adesão à medicação
Medicamentos sintéticos
title_short Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
title_full Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
title_fullStr Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
title_full_unstemmed Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
title_sort Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis : data from a large real-life cohort
author Gomides, Ana Paula Monteiro
author_facet Gomides, Ana Paula Monteiro
Xavier, Ricardo Machado
Pinheiro, Geraldo da Rocha Castelar
author_role author
author2 Xavier, Ricardo Machado
Pinheiro, Geraldo da Rocha Castelar
author2_role author
author
dc.contributor.author.fl_str_mv Gomides, Ana Paula Monteiro
Xavier, Ricardo Machado
Pinheiro, Geraldo da Rocha Castelar
dc.subject.por.fl_str_mv Artrite reumatóide
Antirreumáticos
Adesão à medicação
Medicamentos sintéticos
topic Artrite reumatóide
Antirreumáticos
Adesão à medicação
Medicamentos sintéticos
description The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
publishDate 2019
dc.date.issued.fl_str_mv 2019
dc.date.accessioned.fl_str_mv 2020-12-17T04:09:46Z
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/216608
dc.identifier.issn.pt_BR.fl_str_mv 1932-6203
dc.identifier.nrb.pt_BR.fl_str_mv 001119499
identifier_str_mv 1932-6203
001119499
url http://hdl.handle.net/10183/216608
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv PloS one. San Francisco. Vol. 14, no. 3 (2019), e0213219, 7 p.
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/216608/3/001119499.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/216608/4/001119499-02.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/216608/1/001119499.pdf
http://www.lume.ufrgs.br/bitstream/10183/216608/2/001119499-02.pdf
bitstream.checksum.fl_str_mv ce63baec6093bf82da376483b3521a8b
2d010f75fdbbc1104a5adeb568e150bd
91a9512521ad2d2a3116084368d593bb
9d8ad916eb6c4bca597effeb900c0783
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv lume@ufrgs.br
_version_ 1817725084144500736